Discover how newly cleared weekly basal insulin efsitora reshapes type 2 diabetes care—QWINT results, hypoglycemia edge, and dosing tips.
News|Articles|October 8, 2025
Q3 2025 Recap: Ophthalmology News and Updates
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.
Advertisement
Advertisement
The third quarter of 2025 saw a slew of critical trial results, from investigating treatment interval extension in
Related to this article
FDA clears Eli Lilly’s Onswik weekly insulin from QWINT trials, cutting injections for type 2 diabetes while matching daily basal control.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.
Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.
Advertisement
Advertisement